Therapeutic Type: Disease modification

  • AAV α-synuclein overexpressing non-human primate

    Model Overview AAV1/2-A53T-α-synuclein vectors are injected bilaterally into the substantia nigra of macaques using MRI-based stereotactic techniques. Four injection sites per hemisphere are used to ensure complete viral coverage of the substantia nigra. Degeneration of dopaminergic neurons occurs over several weeks allowing test compounds to be evaluated for disease modifying potential. Some implementations of the…

  • AAV α-synuclein over-expressing rodent

    Model Overview AAV1/2-hA53T-α-synuclein vectors are injected unilaterally into the substantia nigra of rats or mice using stereotaxic techniques. Degeneration of dopaminergic neurons occurs over several weeks allowing test compounds to be evaluated for disease modifying potential. Robust loss on dopaminergic endpoints Dopaminergic cell loss develops over time so that at 6 weeks post-surgery there is…

  • MPTP-lesioned mouse

    Model Overview Various iterations of the MPTP-lesioned mouse are offered by Atuka. In our most commonly used model, MPTP (25 mg/kg, i.p.) is administered to C57bl/6 mice once daily for 5 days. This leads to a loss of tyrosine hydroxylase positive neurons in the substantia nigra that is stable over a period of weeks. Test…